US2019060351A1PendingUtilityA1
Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
Est. expiryJul 10, 2034(~8 yrs left)· nominal 20-yr term from priority
Inventors:Nandita BoseKeith B. GordenAnissa Sh. ChanSteven LeonardoJeremy GraffXiaohong QiuTakashi KangasKathryn FraserAdria Bykowski JonasNadine OttosonRoss Fulton
C07K 16/303C07K 16/2827C07K 16/2863A61K 39/3955C07K 16/3053C07K 16/3061C07K 2317/24C07K 16/44C07K 16/3046A61K 2039/545C07K 2317/73C07K 16/22C07K 16/3015C07K 16/3023A61K 45/06A61K 2039/505A61P 37/04C07K 16/3038A61K 31/716A61K 9/0019A61P 43/00A61P 35/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating a subject having cancer, the method comprising administering soluble β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose and an anti-PD-L1 antibody.
2 . The method according to claim 1 , wherein the cancer is melanoma, renal cell carcinoma, or lung cancer.
3 . The method according to claim 1 , wherein the cancer is breast cancer, pancreatic cancer, colon cancer, and B cell lymphoma.
4 . The method according to claim 1 , wherein the β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose and the anti-PD-L1 antibody are in a single formulation.
5 . The method according to claim 1 , wherein the β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose and the anti-PD-L1 antibody are in separate formulations.
6 . The method according to claim 1 , wherein the β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose is derived from yeast. The method according to claim 6 , wherein the yeast is Saccaromyces cerevisiae.
8 . The method according to claim 1 , wherein the β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose stimulates the subject's immune system.
9 . The method according to claim 1 , wherein the anti-PD-L1 antibody is a non-complement-activating antibody.
10 . The method according to claim 1 , wherein the anti-PD-L1 antibody is an Fc-engineered IgG 1 antibody.
11 . The method according to claim 1 , wherein the anti-PD-L1 antibody is an IgG 4 antibody.
12 . The method according to claim 1 , wherein the β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose and the anti-PD-L1 antibody are administered intravenously.
13 . The method according to claim 1 , wherein the method further comprises administration of a tumor targeting antibody.
14 . The method according to claim 1 , wherein the method further comprises beta-glucan antibodies.
15 . The method according to claim 1 , wherein the has high response toward soluble β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose.
16 . A method of stimulating a subject's immune system against cancer cells, the method comprising administering soluble β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose and an anti-PD-L1 antibody.
17 . The method according to claim 16 , wherein the immune stimulation comprises activation of M1 macrophages, N1 neutrophils, NK cells, T cells, B cells or dendritic cells.
18 . The method according to claim 16 , wherein the immune stimulation comprises activation of interleukin-12, interferon-γ, tumor-necrosis factor α, or a combination thereof.
19 . A method of removing immune suppression in a tumor microenvironment, the method comprising administering soluble β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose and an anti-PD-L1 antibody.
20 . The method according to claim 19 , wherein the method comprises suppressin of M2 macrophages, N2 neutrophils, myeloid-derived suppressor cells, or a combination thereofCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.